Related references
Note: Only part of the references are listed.A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies
Michael J. Pishvaian et al.
CANCER (2012)
The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination
Graham Skelhorne-Gross et al.
PPAR RESEARCH (2012)
Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer
Takako Eguchi Nakajima et al.
CANCER SCIENCE (2010)
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro et al.
LANCET ONCOLOGY (2010)
Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats
Kulbhushan Tikoo et al.
BMC CANCER (2009)
Peroxisome Proliferator-Activated Receptor gamma Pathway Targeting in Carcinogenesis: Implications for Chemoprevention
Frank Ondrey
CLINICAL CANCER RESEARCH (2009)
Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model
Naomi Shimazaki et al.
EUROPEAN JOURNAL OF CANCER (2008)
Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer
Raphael A. Nemenoff et al.
PPAR RESEARCH (2008)
PPAR gamma and MEK Interactions in Cancer
Elke Burgermeister et al.
PPAR RESEARCH (2008)
Synergy between PPARγ ligands and platinum-based drugs in cancer
Geoffrey D. Girnun et al.
CANCER CELL (2007)
RS5444, a novel PPAR-γ agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells
Lu Chen et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2006)
Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1
JA Copland et al.
ONCOGENE (2006)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein
N Maeda et al.
DIABETES (2001)
Share Paper
